167 related articles for article (PubMed ID: 38527258)
1. Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
Tarhini AA; Castellano E; Eljilany I
Cancer J; 2024 Mar-Apr 01; 30(2):54-70. PubMed ID: 38527258
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
4. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
5. Novel adjuvant options for cutaneous melanoma.
Dimitriou F; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Therapy of Melanoma.
Tarhini AA
Hematol Oncol Clin North Am; 2021 Feb; 35(1):73-84. PubMed ID: 33759774
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
Davar D; Tarhini AA; Kirkwood JM
Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
[TBL] [Abstract][Full Text] [Related]
10. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
12. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
Bhave P; Haydon A
Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
[TBL] [Abstract][Full Text] [Related]
13. Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy.
Tarhini AA; Lorigan P; Leachman S
Am Soc Clin Oncol Educ Book; 2017; 37():651-660. PubMed ID: 28561661
[TBL] [Abstract][Full Text] [Related]
14. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.
van Akkooi ACJ; Blank C; Eggermont AMM
Eur J Cancer; 2023 Mar; 182():38-42. PubMed ID: 36738540
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Patel SP; Othus M; Chen Y; Wright GP; Yost KJ; Hyngstrom JR; Hu-Lieskovan S; Lao CD; Fecher LA; Truong TG; Eisenstein JL; Chandra S; Sosman JA; Kendra KL; Wu RC; Devoe CE; Deutsch GB; Hegde A; Khalil M; Mangla A; Reese AM; Ross MI; Poklepovic AS; Phan GQ; Onitilo AA; Yasar DG; Powers BC; Doolittle GC; In GK; Kokot N; Gibney GT; Atkins MB; Shaheen M; Warneke JA; Ikeguchi A; Najera JE; Chmielowski B; Crompton JG; Floyd JD; Hsueh E; Margolin KA; Chow WA; Grossmann KF; Dietrich E; Prieto VG; Lowe MC; Buchbinder EI; Kirkwood JM; Korde L; Moon J; Sharon E; Sondak VK; Ribas A
N Engl J Med; 2023 Mar; 388(9):813-823. PubMed ID: 36856617
[TBL] [Abstract][Full Text] [Related]
17. Systemic adjuvant therapy for high-risk cutaneous melanoma.
Kobeissi I; Tarhini AA
Ther Adv Med Oncol; 2022; 14():17588359221134087. PubMed ID: 36324735
[TBL] [Abstract][Full Text] [Related]
18. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
Olszanski AJ
J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
[TBL] [Abstract][Full Text] [Related]
19. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced
Atkins MB; Lee SJ; Chmielowski B; Tarhini AA; Cohen GI; Truong TG; Moon HH; Davar D; O'Rourke M; Stephenson JJ; Curti BD; Urba WJ; Brell JM; Funchain P; Kendra KL; Ikeguchi AP; Jaslowski A; Bane CL; Taylor MA; Bajaj M; Conry RM; Ellis RJ; Logan TF; Laudi N; Sosman JA; Crockett DG; Pecora AL; Okazaki IJ; Reganti S; Chandra S; Guild S; Chen HX; Streicher HZ; Wolchok JD; Ribas A; Kirkwood JM
J Clin Oncol; 2023 Jan; 41(2):186-197. PubMed ID: 36166727
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J; Mandala M; Del Vecchio M; Gogas HJ; Arance AM; Cowey CL; Dalle S; Schenker M; Chiarion-Sileni V; Marquez-Rodas I; Grob JJ; Butler MO; Middleton MR; Maio M; Atkinson V; Queirolo P; Gonzalez R; Kudchadkar RR; Smylie M; Meyer N; Mortier L; Atkins MB; Long GV; Bhatia S; Lebbé C; Rutkowski P; Yokota K; Yamazaki N; Kim TM; de Pril V; Sabater J; Qureshi A; Larkin J; Ascierto PA;
N Engl J Med; 2017 Nov; 377(19):1824-1835. PubMed ID: 28891423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
